Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic

Many patients with ER+ HER2− primary breast cancer are being deferred from surgery to neoadjuvant endocrine therapy (NeoET) during the COVID-19 pandemic. We have collated data from multiple international trials of presurgical endocrine therapy in order to provide guidance on the identification of pa...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	NPJ breast cancer 2020-06, Vol.6 (1), p.21-21, Article 21
Hauptverfasser:	Dowsett, Mitch, Ellis, Matthew J., Dixon, J. Michael, Gluz, Oleg, Robertson, John, Kates, Ronald, Suman, Vera J., Turnbull, Arran K., Nitz, Ulrike, Christgen, Matthias, Kreipe, Hans, Kuemmel, Sherko, Bliss, Judith M., Barry, Peter, Johnston, Stephen R., Jacobs, Samuel A., Ma, Cynthia X., Smith, Ian E., Harbeck, Nadia
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1347 692/4028/67/1347 Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Cancer therapies Cell Biology Coronaviruses COVID-19 Endocrine therapy Human Genetics Oncology Pandemics Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!